Nitric oxide and prostacyclin pathways: An integrated mechanism that limits myocardial infarction progression in anaesthetized rats

Giuseppe Rossoni, Barbara Manfredi, Vito De Gennaro Colonna, Anna Teresa Brini, Gianluca Polvani, Maria Giovanna Clement, Ferruccio Berti

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Nitric oxide (NO) and cyclooxygenase-derived prostaglandins, such as prostacyclin (PGI 2), are involved in vascular homeostasis. To better understand the reciprocal role of both NO and PGI 2 on myocardial infarction in the rat, we have investigated the cardioprotective effect of nitro-naproxen, isosorbide dinitrate (ISDN), l-arginine, defibrotide and naproxen. In this study, male Wistar rats were treated orally once a day for 5 consecutive days with the compounds under investigation and then, under anesthesia, the animals were subjected to acute myocardial ischemia (30 min) and reperfusion (120 min). Systemic blood pressure, left ventricular pressure and related parameters of cardiac mechanics were recorded. Ventricular arrhythmias and infarct size of the left ventricular wall were also evaluated. Furthermore, cardiac myeloperoxidase (MPO) and plasma creatine phosphokinase (CPK) activities were determined. Defibrotide, nitro-naproxen, ISDN and l-arginine all provided a cardioprotection characterized by significant prevention of arrhythmias with high survival rate of the rats. Infarct size restriction was paralleled by reduction of both cardiac MPO and plasma CK. Cardioprotection of nitro-naproxen, ISDN and l-arginine involve nitrites/nitrates and PGI 2-increased in the circulation associated to a reduction of thromboxane B 2 (TXB 2) in the blood. Defibrotide displays a cardioprotection by increasing PGI 2 release and by reducing TXB 2 in the blood. Naproxen was devoid a lower protecting activity on myocardial infarction, and PGI 2 inhibition may have played a critical role in this context. The results suggested that the increase of both NO and PGI 2 brings about a cascade of integrated cellular and molecular events which are of paramount importance in prevention of myocardial ischemic insult.

Original languageEnglish
Pages (from-to)359-366
Number of pages8
JournalPharmacological Research
Volume53
Issue number4
DOIs
Publication statusPublished - Apr 2006

Fingerprint

Naproxen
Epoprostenol
Nitric Oxide
Isosorbide Dinitrate
Myocardial Infarction
Arginine
Thromboxanes
Peroxidase
Cardiac Arrhythmias
Ventricular Pressure
Prostaglandin-Endoperoxide Synthases
Creatine Kinase
Nitrites
Mechanics
Nitrates
Reperfusion
Myocardial Ischemia
Blood Vessels
Wistar Rats
Homeostasis

Keywords

  • Cardioprotection
  • Ischemia-reperfusion
  • Myocardial infarction
  • Nitric oxide
  • Prostacyclin

ASJC Scopus subject areas

  • Pharmacology

Cite this

Nitric oxide and prostacyclin pathways : An integrated mechanism that limits myocardial infarction progression in anaesthetized rats. / Rossoni, Giuseppe; Manfredi, Barbara; De Gennaro Colonna, Vito; Brini, Anna Teresa; Polvani, Gianluca; Clement, Maria Giovanna; Berti, Ferruccio.

In: Pharmacological Research, Vol. 53, No. 4, 04.2006, p. 359-366.

Research output: Contribution to journalArticle

Rossoni, Giuseppe ; Manfredi, Barbara ; De Gennaro Colonna, Vito ; Brini, Anna Teresa ; Polvani, Gianluca ; Clement, Maria Giovanna ; Berti, Ferruccio. / Nitric oxide and prostacyclin pathways : An integrated mechanism that limits myocardial infarction progression in anaesthetized rats. In: Pharmacological Research. 2006 ; Vol. 53, No. 4. pp. 359-366.
@article{f7ec1355b13f4b189be818b1c422f4c1,
title = "Nitric oxide and prostacyclin pathways: An integrated mechanism that limits myocardial infarction progression in anaesthetized rats",
abstract = "Nitric oxide (NO) and cyclooxygenase-derived prostaglandins, such as prostacyclin (PGI 2), are involved in vascular homeostasis. To better understand the reciprocal role of both NO and PGI 2 on myocardial infarction in the rat, we have investigated the cardioprotective effect of nitro-naproxen, isosorbide dinitrate (ISDN), l-arginine, defibrotide and naproxen. In this study, male Wistar rats were treated orally once a day for 5 consecutive days with the compounds under investigation and then, under anesthesia, the animals were subjected to acute myocardial ischemia (30 min) and reperfusion (120 min). Systemic blood pressure, left ventricular pressure and related parameters of cardiac mechanics were recorded. Ventricular arrhythmias and infarct size of the left ventricular wall were also evaluated. Furthermore, cardiac myeloperoxidase (MPO) and plasma creatine phosphokinase (CPK) activities were determined. Defibrotide, nitro-naproxen, ISDN and l-arginine all provided a cardioprotection characterized by significant prevention of arrhythmias with high survival rate of the rats. Infarct size restriction was paralleled by reduction of both cardiac MPO and plasma CK. Cardioprotection of nitro-naproxen, ISDN and l-arginine involve nitrites/nitrates and PGI 2-increased in the circulation associated to a reduction of thromboxane B 2 (TXB 2) in the blood. Defibrotide displays a cardioprotection by increasing PGI 2 release and by reducing TXB 2 in the blood. Naproxen was devoid a lower protecting activity on myocardial infarction, and PGI 2 inhibition may have played a critical role in this context. The results suggested that the increase of both NO and PGI 2 brings about a cascade of integrated cellular and molecular events which are of paramount importance in prevention of myocardial ischemic insult.",
keywords = "Cardioprotection, Ischemia-reperfusion, Myocardial infarction, Nitric oxide, Prostacyclin",
author = "Giuseppe Rossoni and Barbara Manfredi and {De Gennaro Colonna}, Vito and Brini, {Anna Teresa} and Gianluca Polvani and Clement, {Maria Giovanna} and Ferruccio Berti",
year = "2006",
month = "4",
doi = "10.1016/j.phrs.2006.01.004",
language = "English",
volume = "53",
pages = "359--366",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press",
number = "4",

}

TY - JOUR

T1 - Nitric oxide and prostacyclin pathways

T2 - An integrated mechanism that limits myocardial infarction progression in anaesthetized rats

AU - Rossoni, Giuseppe

AU - Manfredi, Barbara

AU - De Gennaro Colonna, Vito

AU - Brini, Anna Teresa

AU - Polvani, Gianluca

AU - Clement, Maria Giovanna

AU - Berti, Ferruccio

PY - 2006/4

Y1 - 2006/4

N2 - Nitric oxide (NO) and cyclooxygenase-derived prostaglandins, such as prostacyclin (PGI 2), are involved in vascular homeostasis. To better understand the reciprocal role of both NO and PGI 2 on myocardial infarction in the rat, we have investigated the cardioprotective effect of nitro-naproxen, isosorbide dinitrate (ISDN), l-arginine, defibrotide and naproxen. In this study, male Wistar rats were treated orally once a day for 5 consecutive days with the compounds under investigation and then, under anesthesia, the animals were subjected to acute myocardial ischemia (30 min) and reperfusion (120 min). Systemic blood pressure, left ventricular pressure and related parameters of cardiac mechanics were recorded. Ventricular arrhythmias and infarct size of the left ventricular wall were also evaluated. Furthermore, cardiac myeloperoxidase (MPO) and plasma creatine phosphokinase (CPK) activities were determined. Defibrotide, nitro-naproxen, ISDN and l-arginine all provided a cardioprotection characterized by significant prevention of arrhythmias with high survival rate of the rats. Infarct size restriction was paralleled by reduction of both cardiac MPO and plasma CK. Cardioprotection of nitro-naproxen, ISDN and l-arginine involve nitrites/nitrates and PGI 2-increased in the circulation associated to a reduction of thromboxane B 2 (TXB 2) in the blood. Defibrotide displays a cardioprotection by increasing PGI 2 release and by reducing TXB 2 in the blood. Naproxen was devoid a lower protecting activity on myocardial infarction, and PGI 2 inhibition may have played a critical role in this context. The results suggested that the increase of both NO and PGI 2 brings about a cascade of integrated cellular and molecular events which are of paramount importance in prevention of myocardial ischemic insult.

AB - Nitric oxide (NO) and cyclooxygenase-derived prostaglandins, such as prostacyclin (PGI 2), are involved in vascular homeostasis. To better understand the reciprocal role of both NO and PGI 2 on myocardial infarction in the rat, we have investigated the cardioprotective effect of nitro-naproxen, isosorbide dinitrate (ISDN), l-arginine, defibrotide and naproxen. In this study, male Wistar rats were treated orally once a day for 5 consecutive days with the compounds under investigation and then, under anesthesia, the animals were subjected to acute myocardial ischemia (30 min) and reperfusion (120 min). Systemic blood pressure, left ventricular pressure and related parameters of cardiac mechanics were recorded. Ventricular arrhythmias and infarct size of the left ventricular wall were also evaluated. Furthermore, cardiac myeloperoxidase (MPO) and plasma creatine phosphokinase (CPK) activities were determined. Defibrotide, nitro-naproxen, ISDN and l-arginine all provided a cardioprotection characterized by significant prevention of arrhythmias with high survival rate of the rats. Infarct size restriction was paralleled by reduction of both cardiac MPO and plasma CK. Cardioprotection of nitro-naproxen, ISDN and l-arginine involve nitrites/nitrates and PGI 2-increased in the circulation associated to a reduction of thromboxane B 2 (TXB 2) in the blood. Defibrotide displays a cardioprotection by increasing PGI 2 release and by reducing TXB 2 in the blood. Naproxen was devoid a lower protecting activity on myocardial infarction, and PGI 2 inhibition may have played a critical role in this context. The results suggested that the increase of both NO and PGI 2 brings about a cascade of integrated cellular and molecular events which are of paramount importance in prevention of myocardial ischemic insult.

KW - Cardioprotection

KW - Ischemia-reperfusion

KW - Myocardial infarction

KW - Nitric oxide

KW - Prostacyclin

UR - http://www.scopus.com/inward/record.url?scp=33645959518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645959518&partnerID=8YFLogxK

U2 - 10.1016/j.phrs.2006.01.004

DO - 10.1016/j.phrs.2006.01.004

M3 - Article

C2 - 16488624

AN - SCOPUS:33645959518

VL - 53

SP - 359

EP - 366

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

IS - 4

ER -